Lyka Labs Limited has made several significant announcements following its recent Board of Directors meeting. The pharmaceutical company has approved its quarterly results and revealed important changes in its management structure.

Quarterly Financial Results Approved

The Board of Directors of Lyka Labs has approved the unaudited financial results for the quarter ended June 30, 2025. These results encompass both standalone and consolidated statements, providing a comprehensive view of the company's financial performance for the first quarter of the fiscal year 2025-26.

Company Secretary Resignation

In a notable management change, Mr. Shekhar R Singh has resigned from his position as Company Secretary and Compliance Officer of Lyka Labs. The resignation, which was tendered on July 1, 2025, citing pursuit of alternative career opportunities, will be effective from the close of business hours on August 1, 2025.

Mr. Singh has committed to fulfilling his responsibilities, including those related to the upcoming 46th Annual General Meeting (AGM), and ensuring a smooth transition before his departure. The Board has acknowledged Mr. Singh's contributions during his tenure with the company.

Appointment of Internal Auditor

In a move to strengthen its internal audit function, Lyka Labs has appointed Sudit K Parekh & Co. LLP as the Internal Auditor for the financial year 2025-26. The Mumbai-based chartered accountancy firm, with registration number 110512W/W100378, brings extensive experience in internal audit assignments to the role.

Board Meeting Details

The Board meeting, which commenced at 11:10 am and concluded at 12:25 pm on August 1, 2025, addressed these key matters. The company has duly informed the stock exchanges of these developments in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

These corporate actions reflect Lyka Labs' commitment to maintaining transparent communication with its stakeholders and ensuring robust corporate governance practices. Investors and market observers will likely keep a close watch on how these changes impact the company's operations and performance in the coming quarters.

Lyka Labs , a pharmaceutical company, has reported a significant turnaround in its financial performance for the fourth quarter, marking a return to profitability, showcasing strong revenue growth, and improved EBITDA.

Profit Turnaround

The company posted a consolidated net profit of ₹18.00 million in the fourth quarter, a remarkable improvement from the ₹21.00 million loss reported in the same quarter of the previous year. This positive shift indicates a successful execution of the company's strategies to enhance profitability.

EBITDA and Margin Improvement

Lyka Labs reported a substantial increase in EBITDA, which rose to ₹41.00 million from ₹20.00 million in the same quarter of the previous year. The EBITDA margin also saw significant improvement, increasing to 12.23% from 7.31% year-over-year. This enhancement in both EBITDA and margin reflects the company's improved operational efficiency and profitability.

Quarter-on-Quarter Performance

While the fourth quarter profit of ₹18.00 million represents a decrease from the ₹27.00 million profit recorded in the previous quarter, it still maintains the company's streak of profitability, suggesting consistent positive performance.

Revenue Growth

Lyka Labs demonstrated robust top-line growth, with revenue for the fourth quarter reaching ₹334.00 million. This figure represents a significant increase from ₹278.00 million reported in the corresponding quarter of the previous year, translating to a year-over-year growth of approximately 20%.

Financial Overview

To provide a clearer picture of Lyka Labs' financial performance, here's a summary of the key figures:

The company's ability to turn a profit amid challenging market conditions, improve its revenue significantly year-over-year, and enhance its EBITDA and margin suggests a positive outlook for Lyka Labs . The pharmaceutical sector continues to be a critical industry, and Lyka Labs' performance indicates its resilience and potential for growth in the coming periods.